News & Resources
December 14, 2020

Like It? Share It

Pfizer-BioNTech COVID-19 Vaccine Review and Analysis

Resources

The Food and Drug Administration approved an Emergency Use Authorization Friday, Dec. 11, for the Pfizer-BioNTech COVID-19 vaccine. This triggered vaccine shipments across the United States beginning with the first wave targeting healthcare workers and nursing home residents.

The TeamHealth Emerging Infectious Disease Task Force (EIDT) has reached the following, unanimous conclusion based on the Pfizer-BioNTech study data:

The EIDT strongly recommends vaccination with the Pfizer-BioNTech COVID-19 vaccine for all adults above 16 years of age in every racial and ethnic demographic regardless of COVID-19 risk factors, prior COVID-19 infection or other underlying health conditions, unless there are clear, existing contraindications to receiving any vaccine.

The EIDT is committed to synthesizing and offering you the most up-to-date information related to COVID-19. Download the full EIDT Pfizer-BioNTech COVID-19 vaccine analysis below.

 

Download